In-vivo Study Shows CK1D Inhibitors Improve Cognition in Alzheimer’s Model
News Jan 03, 2013
Proteome Sciences has announced that the in-vivo study of its proprietary CK1D inhibitor programme in Alzheimer’s disease was completed as anticipated in December 2012.
Having already confirmed earlier in the year that CK1D inhibitors block tau phosphorylation in cell lines in an in-vitro study, Proteome Sciences has announced that both of its lead compounds for CK1D have demonstrated improved cognitive function in the current study.
These results provide important in-vivo proof of principle and demonstrate the efficacy of our compounds.
The next phase will start immediately in January to undertake and complete a comprehensive assessment of biological indicators and drug levels in various tissues.
Dr. Ian Pike, Chief Operating Officer commented :- "These results further validate PS Biomarker Services’ proteomic approach in discovery of new drug targets in challenging diseases. By diligently following the tau hypothesis of Alzheimer's disease we have been able to develop exciting new therapeutic strategies that are increasingly recognized by the scientific community as important components of the fight to halt Alzheimer's disease progression. We believe that inhibiting CK1D will be an important component in treatment of AD and we will concentrate on rapidly developing these assets."
Christopher Pearce, CEO said :- “Our goal was to deliver in-vivo proof of principle for CK1D in Alzheimer’s disease. We are delighted that this has been successfully achieved in 2012. These results are most timely as major pharmaceutical companies and academia have increasingly been switching attention to the importance of tau tangles in combination with amyloid aggregation in Alzheimer’s. In light of UK Government's recent commitment to fully fund NHS access to novel treatments for AD we believe there is significant potential for CK1D inhibitors to positively affect the lives of sufferers and their carers. We will continue to push our CK1D programme forward and will actively engage with the pharmaceutical industry to bring our compounds to clinical trials as soon as possible”.
Decoding the 3-D Structure of HuntingtinNews
Mutations on a single gene, the huntingtin gene, are the cause of Huntington's disease. They lead to an incorrect form of the correspondent protein. With the help of cryo-electron microscopy, researchers have now decoded the three-dimensional, molecular structure of the healthy human huntingtin protein.READ MORE